Written by PX1 Research Team
PX1 chemists and research educators with hands-on experience in US-based peptide manufacturing, HPLC / mass-spectrometry lot testing, and endotoxin QC. All content is citation-backed and peer-reviewed for accuracy.
Wolverine Stack (BPC-157 + TB-500): Research Dosage Chart & Protocol
Research Guide
Reviewed By
PX1 QC — Analytical Chemistry Team
Every article is reviewed by PX1's in-house analytical team for accuracy on mechanism, dosing ranges reported in the literature, and lab-handling guidance. We do not publish clinical or medical advice.
Quick answer
The Wolverine stack pairs BPC-157 with TB-500 in tissue-repair research models. Mechanisms, published dose ranges, reconstitution math, and a reference chart.
Key takeaways
- Concentration: 2,500 mcg/mL
- 250 mcg = 0.10 mL = 10 units on a U-100 insulin syringe
- Concentration: 2,500 mcg/mL
- 2,500 mcg = 1.00 mL = 100 units on a U-100 syringe
What the Wolverine stack is
The "Wolverine stack" is the pairing of BPC-157 with TB-500 (thymosin beta-4 fragment), used together in tissue-repair and angiogenesis research models. The two peptides are combined because their published mechanisms are complementary rather than overlapping.
| Peptide | Primary published mechanism | Typical research role |
|---|---|---|
| BPC-157 | Upregulates VEGFR2 signaling and the FAK–paxillin pathway; promotes local angiogenesis | Localized tissue models — tendon, ligament, gut epithelium |
| TB-500 | Actin-sequestering peptide; promotes cell migration and endothelial differentiation | Systemic models — cell migration, wound closure kinetics |
Reference dose ranges reported in the literature
Ranges below reflect commonly cited research-model figures. They are reference points for protocol design, not recommendations for any use in humans.
| Compound | Reported research range | Frequency in published models | Typical model duration |
|---|---|---|---|
| BPC-157 | 200–500 mcg per administration | Once or twice daily | 4–6 weeks |
| TB-500 | 2–2.5 mg per administration | Twice weekly in loading phase | 4–6 weeks loading |
| TB-500 (maintenance) | 2–2.5 mg | Once every 1–2 weeks | Model-dependent |
Many published tissue-repair models run a 4-week loading phase with both compounds, followed by a maintenance phase using TB-500 alone at reduced frequency.
Reconstitution math
Working concentration determines draw volume. Two common setups:
BPC-157, 5 mg vial + 2 mL bacteriostatic water
- Concentration: 2,500 mcg/mL
- 250 mcg = 0.10 mL = 10 units on a U-100 insulin syringe
TB-500, 10 mg vial + 4 mL bacteriostatic water
- Concentration: 2,500 mcg/mL
- 2,500 mcg = 1.00 mL = 100 units on a U-100 syringe
Run your own numbers with the reconstitution calculator.
Sample 6-week reference schedule
| Week | BPC-157 | TB-500 |
|---|---|---|
| 1 | 250 mcg × 2 daily | 2.5 mg × 2 weekly |
| 2 | 250 mcg × 2 daily | 2.5 mg × 2 weekly |
| 3 | 250 mcg × 2 daily | 2.5 mg × 2 weekly |
| 4 | 250 mcg × 2 daily | 2.5 mg × 2 weekly |
| 5 | 250 mcg daily | 2.5 mg weekly |
| 6 | 250 mcg daily | 2.5 mg weekly |
Handling and storage
Both compounds are supplied lyophilized. Store sealed vials at -20°C for long-term storage; reconstituted solution at 2–8°C, protected from light, used within roughly 30 days. Avoid repeated freeze–thaw cycles — aliquot instead. Never shake a reconstituted vial; swirl gently.
Documentation to require
Both peptides in this stack are widely counterfeited. Require a lot-matched COA with an HPLC chromatogram, mass-spectrometry identity confirmation, and an endotoxin (LAL) result. PX1 publishes all three per lot at /purity-reports.
- BPC-157: /research/bpc-157-complete-guide
- TB-500: /research/tb-500-thymosin-beta-4-guide
Research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.